Cargando…
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
BACKGROUND: The FDA recently approved an anti-CTLA-4 antibody (Iplimumab) for the treatment of metastatic melanoma. This decision was based on Phase III results, which demonstrate that blocking this immune checkpoint provides a survival advantage in patients with advanced disease. As a single agent,...
Autores principales: | Wada, Satoshi, Jackson, Christopher M, Yoshimura, Kiyoshi, Yen, Hung-Rong, Getnet, Derese, Harris, Timothy J, Goldberg, Monica V, Bruno, Tullia C, Grosso, Joseph F, Durham, Nicholas, Netto, George J, Pardoll, Drew M, Drake, Charles G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666941/ https://www.ncbi.nlm.nih.gov/pubmed/23557194 http://dx.doi.org/10.1186/1479-5876-11-89 |
Ejemplares similares
-
Immunotherapy earns its spot in the ranks of cancer therapy
por: Pardoll, Drew, et al.
Publicado: (2012) -
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018) -
Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
por: Belcaid, Zineb, et al.
Publicado: (2014) -
Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
por: Youlin, Kuang, et al.
Publicado: (2012) -
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
por: Fan, Xiaozhou, et al.
Publicado: (2014)